Abstract:Introduction: Hepatitis E virus (HEV) genotype 3 is the major cause of acute viral hepatitis in several European countries. It is acquired mainly by ingesting contaminated pork, but has also been reported to be transmitted through blood transfusion. Although most HEV infections, including those via blood products, are usually self-limiting, they may become chronic in immunocompromised persons. It is thus essential to identify HEV-infected blood donations to prevent transmission to vulnerable recipients. Aims: Prior to the decision whether to introduce HEV RNA screening for all Swiss blood donations, a 2-year nationwide prevalence study was conducted. Methods: All blood donations were screened in pools of 12–24 samples at five regional blood donation services, and HEV RNA-positive pools were subsequently resolved to the individual donation index donation (X). The viral load, HEV IgG and IgM serology, and HEV genotype were determined. Follow-up investigations were conducted on future control donations (X + 1) and previous archived donations of the donor (X − 1) where available. Results: Between October 2018 and September 2020, 541,349 blood donations were screened and 125 confirmed positive donations were identified (prevalence 1:4331 donations). At the time of blood donation, the HEV RNA-positive individuals were symptom-free. The median viral load was 554 IU/mL (range: 2.01–2,500,000 IU/mL). Men (88; 70%) were more frequently infected than women (37; 30%), as compared with the sex distribution in the Swiss donor population (57% male/43% female, p < 0.01). Of the 106 genotyped cases (85%), all belonged to genotype 3. Two HEV sub-genotypes predominated; 3h3 (formerly 3s) and 3c. The remaining sub-genotypes are all known to circulate in Europe. Five 3ra genotypes were identified, this being a variant associated with rabbits. In total, 85 (68%) X donations were negative for HEV IgM and IgG. The remaining 40 (32%) were positive for HEV IgG and/or IgM, and consistent with an active infection. We found no markers of previous HEV in 87 of the 89 available and analyzed archive samples (X − 1). Two donors were HEV IgG-positive in the X − 1 donation suggesting insufficient immunity to prevent HEV reinfection. Time of collection of the 90 (72%) analyzed X + 1 donations varied between 2.9 and 101.9 weeks (median of 35 weeks) after X donation. As expected, none of those tested were positive for HEV RNA. Most donors (89; 99%) were positive for anti-HEV lgG/lgM (i.e., seroconversion). HEV lgM-positivity (23; 26%) indicates an often-long persistence of lgM antibodies post-HEV infection. Conclusion: The data collected during the first year of the study provided the basis for the decision to establish mandatory HEV RNA universal screening of all Swiss blood donations in minipools, a vital step in providing safer blood for all recipients, especially those who are immunosuppressed.

New Immunoassays for Total, IgA and IgM Antibodies Against Hepatitis E Virus: Prevalence in Italian Blood Donors and Patients with Chronic Liver or Kidney Diseases.

Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays.

International Collaborative Survey on Epidemiology of Hepatitis E Virus in 11 Countries.

[Research Progress in Laboratory Diagnostic Methods for HEV Infection].

Unexpected long‐lasting anti‐HEV IgM positivity: Is HEV antigen a better serological marker for hepatitis E infection diagnosis?

Empty Virus-Like Particle-Based Enzyme-Linked Immunosorbent Assay for Antibodies to Hepatitis E Virus

A Valuable Antigen Detection Method for Diagnosis of Acute Hepatitis E

Evaluation of an Antigen Assay for Diagnosing Acute and Chronic Hepatitis E Genotype 4 Infection

Epidemiology of HEV Infection in Blood Donors in Southern Switzerland

Prevalence of Acute Hepatitis E Virus Infections in Swiss Blood Donors 2018–2020

Calibrating Hepatitis E Virus Serological Assays Using Asymptomatic Specimens Obtained in Japan

Detection of Hev Antigen As A Novel Marker for the Diagnosis of Hepatitis E

Molecular Characterization and Seroprevalence of Hepatitis E Virus in Inflammatory Bowel Disease Patients and Solid Organ Transplant Recipients

A New Enzyme Immunoassay for the Detection of Antibody to Hepatitis E Virus.

An Optimized High-Throughput Neutralization Assay For Hepatitis E Virus (Hev) Involving Detection Of Secreted Porf2

Profile of Clinical Characteristics and Serologic Markers of Sporadic Hepatitis E in a Community Cohort Study.

Hepatitis E virus seroprevalence and molecular study among blood donors in China.

[Investigation Epidemiology and Sub-Clinical Infection of Hepatitis E in Voluntary Blood Donors in South Zhejiang].

Chronic inflammatory demyelinating polyneuropathy and HEV antibody status: A case-control study from Lazio, Italy

Serological and Molecular Study of Hepatitis E Virus among Illegal Blood Donors

Hepatitis E virus infections in German blood donors: results of 8 years of screening, 2015 to 2022